CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jan. 6, 2016--
Seres Therapeutics Inc. (NASDAQ:MCRB), a leading microbiome therapeutics
company, announced today that Roger Pomerantz, M.D., President, Chief
Executive Officer and Chairman of Seres, will present a company overview
at the 34th annual J.P. Morgan Healthcare Conference in San
Francisco. The presentation will take place on Wednesday, Jan. 13, at 3
p.m. PT at the Westin St. Francis Hotel.
Live audio webcast of the presentation will be available under the
“Investors and Media” section of Seres’ website at www.serestherapeutics.com.
A replay of the presentation will be available approximately one hour
after the event and will be archived on the website for 14 days.
About Seres Therapeutics
Seres Therapeutics Inc. is a leading microbiome therapeutics platform
company developing a novel class of biological drugs that are designed
to treat disease by restoring the function of a dysbiotic microbiome
characterized by an increased presence of pathogenic bacterial species,
where the natural state of bacterial diversity is imbalanced. Seres’
most advanced program, SER-109, has successfully completed a Phase 1b/2
study demonstrating a clinical benefit in patients with recurring Clostridium
difficile infection (CDI) and is currently being evaluated in a
Phase 2 study in recurring CDI. Seres’ second clinical candidate,
SER-287, is being evaluated in a Phase 1b study in patients with
mild-to-moderate ulcerative colitis (UC).
View source version on businesswire.com: http://www.businesswire.com/news/home/20160106005214/en/
Source: Seres Therapeutics Inc.
IR Contact:
Seres Therapeutics
Carlo
Tanzi, Ph.D., 617-203-3467
Head of Investor Relations and Corporate
Communications
Ctanzi@serestherapeutics.com
or
PR
Contact:
Ten Bridge Communications
Dan Quinn,
781-475-7974
Dan@tenbridgecommunications.com